bpc-157 + tb500 + mgf blend Buy / TB-500 10mg | Research Grade Australia BPC-157 + TB-500 10mg Blend
Description
Belosic Halle, K
Pivotal Phase 3 trials Trial SURMOUNT-1 (NEJM 2022) Population 2,539 adults, obesity, no diabetes
Preclinical evidence suggests gastroprotective and anti-inflammatory properties for BPC-157 [2]
Higher concentrations can actually be slightly more stable because there is a lower ratio of water to peptide, which means fewer water molecules available for hydrolysis per peptide molecule
